0001415889-24-009154.txt : 20240326 0001415889-24-009154.hdr.sgml : 20240326 20240326184819 ACCESSION NUMBER: 0001415889-24-009154 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240322 FILED AS OF DATE: 20240326 DATE AS OF CHANGE: 20240326 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lowenthal Richard E CENTRAL INDEX KEY: 0001378550 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39756 FILM NUMBER: 24785239 MAIL ADDRESS: STREET 1: 12481 HIGH BLUFF DRIVE, SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92130 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ARS Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001671858 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 811489190 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 11682 EL CAMINO REAL, SUITE 120 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: 858-771-9307 MAIL ADDRESS: STREET 1: 11682 EL CAMINO REAL, SUITE 120 CITY: SAN DIEGO STATE: CA ZIP: 92130 FORMER COMPANY: FORMER CONFORMED NAME: Silverback Therapeutics, Inc. DATE OF NAME CHANGE: 20160412 4 1 form4-03262024_100309.xml X0508 4 2024-03-22 0001671858 ARS Pharmaceuticals, Inc. SPRY 0001378550 Lowenthal Richard E C/O ARS PHARMACEUTICALS, INC. 11682 EL CAMINO REAL, SUITE 120 SAN DIEGO CA 92130 true true true false PRESIDENT AND CEO 1 Common Stock 4126822 D Common Stock 2024-03-22 4 S 0 1017 9.0298 D 1745082 I By Sarina Tanimoto Charitable Remainder UniTrust Dated January 7, 2020 Common Stock 2024-03-22 4 S 0 1326 9.0132 D 1996131 I By Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006 Common Stock 2024-03-25 4 S 0 47635 9.1238 D 1697447 I By Sarina Tanimoto Charitable Remainder UniTrust Dated January 7, 2020 Common Stock 2024-03-25 4 S 0 47632 9.1236 D 1948499 I By Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006 Common Stock 1696494 I By Richard E. Lowenthal Charitable Remainder UniTrust Dated January 7, 2020 Common Stock 3276854 I By Spouse The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023. The weighted average sale price for the transaction reported was $9.0298, and the range of prices were between $9.00 and $9.06. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. The weighted average sale price for the transaction reported was $9.0132, and the range of prices were between $9.00 and $9.07. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. The shares are held in trust for the benefit of the Reporting Person and his spouse. The Reporting Person and his spouse are trustees of the trust. The weighted average sale price for the transaction reported was $9.1238, and the range of prices were between $9.03 and $9.36. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. The weighted average sale price for the transaction reported was $9.1236, and the range of prices were between $9.03 and $9.36. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. The Reporting Person is trustee of the trust. /s/ Kathleen Scott, Attorney-in-Fact 2024-03-26